(Reuters) – Eli Lilly (NYSE:)’s recently approved obesity drug Zepbound is now available in U.S. pharmacies and could be available to some insured customers at $550 per month or half of the list price, the U.S. drugmaker said on Tuesday.

The company is making the weight-loss drug accessible to adults through its commercial savings card program, where people who are commercially insured with coverage may be eligible to pay as low as $25 for a 1-month or 3-month prescription.

While, adults who are commercially insured without coverage may be eligible to pay as low as $550 for a 1-month prescription.

The drug was approved in November, paving the way for a powerful new rival to Novo Nordisk (NYSE:)’s Wegovy in addressing record obesity rates.

Lilly’s drug tirzepatide has been available as Mounjaro for type 2 diabetes since 2022 and had increasingly been used “off-label” for weight loss while the obesity approval was pending.